The company has developed a multiplex panel for bacterial and yeasts infections that it plans to submit for FDA clearance in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback